Oligonucleotide Synthesis Market

Oligonucleotide Synthesis Market by Product (Drug, Synthesized Oligos (Primer, Probe), Reagents), Type (Custom, Predesign), Application (Therapeutic (ASO, siRNA), Research (PCR), Diagnostic), End User (Hospital, Pharma, CROs) - Global Forecast to 2026

Report Code: BT 2680 Apr, 2021, by marketsandmarkets.com

[246 Pages Report] The global oligonucleotide synthesis market is projected to reach USD 14.1 billion by 2026 from USD 6.3 billion in 2021, at a CAGR of 17.6% during the forecast period. The major factors driving the growth of this market include the increasing use of synthesized oligos in therapeutic applications, increasing government funding, and the growing focus on personalized medicine.

Oligonucleotide Synthesis Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 Impact on the Global Oligonucleotide Synthesis Market

COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 has moved from a regional crisis to a global pandemic. The World Health Organization (WHO) officially declared the outbreak of COVID-19 a pandemic. A mix of established pharmaceutical and biopharmaceutical companies, along with the players of the oligonucleotide synthesis market, have stepped forward to contribute to worldwide research efforts by providing oligo products for developing test kits, treatments, and vaccines that target the infection caused by the novel Coronavirus. Some examples are as follows:

  • In April 2020, Microsynth AG (Switzerland) provided key reagents such as primer-probe sets to PCR testing labs to support molecular diagnostic companies in developing & validating accurate, cutting-edge detection methods and to provide comprehensive genomics expertise for research labs studying coronaviruses. The main contribution includes the supply of RT-qPCR primer-probe sets for SARS-CoV-2 detection and synthesis of primers for NGS-based SARS-CoV-2 high-throughput diagnostic, among others.
  • In June 2020, Bio-Synthesis Inc. (US) delivered ready-to-use cocktail mixes such as the SARS-CoV-2 N1 Oligo Mix, the SARS-CoV-2 N2 Oligo Mix, and the Human RNase P (RP) Oligo Mix for COVID-19 research.
  • In April 2020, TriLink BioTechnologies (a part of Maravai Lifesciences) (US) entered into a partnership with Imperial College London (UK) for the manufacturing of self-amplifying RNA (saRNA) for COVID-19 vaccine development.
  • During the COVID-19 pandemic, Biolegio B.V. (Netherlands) rapidly scaled up production capabilities to deliver primers and probes for RT-qPCR testing of the Coronavirus and have been supplying laboratories and customers sufficient primer and probe sets to perform millions of tests.

The various initiatives by the players of this market and usage of a wide range of oligonucleotide products such as probes and primers in COVID-19 research have helped researchers gain a better understanding of the Coronavirus. Hence, COVID-19 has positively impacted the oligonucleotide synthesis market to a certain extent. However, in 2020 there was a slight decrease in the sales of oligonucleotide-based drugs due to restrictions imposed during the COVID-19 pandemic.

Oligonucleotide Synthesis Market Dynamics

Driver: Increasing government investments for synthetic biology and genome projects

In recent years, governments in various countries have made significant investments in projects related to the field of synthetic biology and genomics. These government investments have played a major role in the development of new technologies. Oligos form an integral part of these technologies, and increasing funding & developments in these fields will drive market growth for oligonucleotides. For instance;

  • In January 2020, the Department of Biotechnology (DBT) initiated the “Genome India Project” (GIP). The project aims to collect 10,000 genetic samples from citizens across India to build a reference genome. Some focus areas of this project are precision health, rare genetic disorders, mutation spectrum of genetic & complex diseases in the Indian population, genetic epidemiology of multifactorial lifestyle diseases, and translational research.
  • In February 2021, the Centre for Process Innovation (CPI) launched a project in the Medicines Manufacturing Innovation Centre in the UK. This project aims to revolutionize the manufacturing of oligonucleotides through a collaboration with AstraZeneca, Exactmer, Novartis, and the UK Research & Innovation. Inclisiran, a small interfering RNA used in the treatment of atherosclerotic cardiovascular disease (ASCVD), would be the first medicine produced at a commercial scale as a result of this collaboration.
  • In August 2019, the Li Ka Shing Foundation (Hongkong) donated USD 63 million to launch a major institute for synthetic biology research at the Hong Kong University of Science and Technology (HKUST). The new institute will conduct research in synthetic biology, combining the materials and processes of biological systems & engineering.
  • In September 2019, a whole-genome sequencing project of USD 224 million was created, forming a partnership of pharmaceutical firms and health experts, which will examine and sequence the genetic code of 500,000 volunteers at the UK Biobank, based in Stockport, UK. The project aims to improve health through genetic research and improve the prevention, diagnosis, and treatment of a wide range of serious and life-threatening illnesses, including cancer, heart diseases, diabetes, arthritis, and dementia.
  • In February 2019, the Minister of Science and Sport (Canada) announced the funding of USD 22.7 million in addition to funding of USD 33.4 million by provincial governments to support 36 research projects through Genome Canada. The projects include various sectors such as health, agriculture, natural resources, and the environment.
  • In January 2019, the National Institutes of Health (NIH) awarded 24 grants to researchers across the US and Canada through the Somatic Cell Genome Editing (SCGE) Program. This group of awards from the SCGE Program totals approximately USD 89 million over four years.

These ongoing government-sponsored projects will lead to improvements in genomic technologies, specifically in DNA sequencing, DNA amplification, NGS, and gene expression. Also, oligos form an integral part of these technologies; therefore, an increase in government-funded projects will positively impact the overall growth of the oligonucleotide synthesis market.

Restraint: Complexities associated with therapeutic oligos

The importance of synthetic oligos as therapeutic drugs for treating diseases has grown significantly in the last decade. Some of the major drivers for this growth are the characterization of more targets following the identification of the human genome, advancements in antisense oligos, and the development of double-stranded siRNA oligos. Therapeutic oligos are also useful in treating diseases ranging from viral infections, respiratory diseases, cancer, and rare diseases such as Duchenne Muscular Dystrophy (DMD), cystic fibrosis, and thrombotic thrombocytopenic purpura.

However, there have been various instances in the past, wherein due to high complexities such as severe side effects, many drugs have been withdrawn or have failed in clinical trial phases. Such instances could become recurrent and may restrain market growth to a certain extend. Below are a few examples of such instances:

  • An oligonucleotide-based drug, Kynamro, was withdrawn in 2012. The Committee for Medical Products (CHMP) was concerned that a high proportion of patients stopped taking medicine within two years mainly due to side effects associated with it. This is considered an important limitation because Kynamro is intended for long-term treatment. The CHMP was also concerned by the potential long-term consequences of liver test results showing a build-up of fat in the liver and increased enzyme levels and was not convinced that the company had proposed sufficient measures to prevent the risk of irreversible liver damage. Moreover, the Committee was concerned that more cardiovascular events were reported in patients taking Kynamro than in patients taking placebo. This prevented the CHMP from concluding that Kynamro’s intended cardiovascular benefit, in terms of reducing cholesterol levels, outweighed its potential cardiovascular risk. Therefore, the CHMP was of the opinion that the benefits of Kynamro did not outweigh its risks and recommended that it be refused marketing authorization.
  • Similarly, in 2011, Pfizer had withdrawn its bid for the European approval of a new use of eye drug, Macugen (an oligonucleotide base drug), to treat a condition linked to diabetes. In its official letter, Pfizer said the withdrawal was based on the fact that the data provided so far did not allow European regulators to conclude on a positive benefit-risk balance for the drug in the new use.

Opportunity: Key players in emerging economies

Countries such as China, India, Singapore, and emerging economies such as Brazil provide significant growth opportunities for the oligonucleotide synthesis markets. This potential is mainly due to the increasing R&D investments by various companies in emerging economies of the Asia Pacific and Latin America regions. . Some recent developments in line with this are as follows:

  • In 2020, IDT (US) opened IDT China, an official business entity in China to better serve its customer base in the region, to reach out to new customers, and provide easier access to its complete portfolio of industry-leading products, including custom DNA and RNA oligos, probes, and primers.
  • In 2019, SPINRAZA (nusinersen), marketed by Biogen, Inc. (US), received approval from the China National Medical Products Association (NMPA) for the treatment of 5q spinal muscular atrophy (SMA). This is expected to drive the oligonucleotide therapeutics market in this region.
  • In 2019, Ajinomoto Co., Inc. (Japan) opened a new development center in Osaka, Japan, expanding its oligonucleotide synthesis and supply capabilities to support growing customer needs. The development center also houses process development labs to support manufacturing activities and R&D labs for the development of novel oligonucleotide manufacturing technologies.
  • In October 2018, Thermo Fisher Scientific launched its next-generation sequencing Center of Excellence Program in the Asia Pacific region. This program establishes strategic research and technical collaborations with major research hospitals, which would, in turn, enable the adoption of oncomine NGS assays made up of oligonucleotides for future clinical applications.
  • In January 2018, the Singapore government launched a synthetic biology R&D program, which will receive USD 19 million (SGD 25 million) over five years. These programs encourage scientists to conduct more research in the field of synthetic biology. Improvements in R&D will support the growth of the pharma and biotech industries in this region, thereby driving the oligonucleotide synthesis market in Singapore.
  • The growing R&D investments in this region will boost research activities in the field of genomics and synthetic biology, which will, in turn, drive the oligonucleotide synthesis market.

Challenge:  Delivery of oligonucleotide drugs to specific targets

The application of gene therapy and antisense therapy to mediate tumor regression is well demonstrated in experimental and clinical settings. However, translating this into clinical applications at large still remains an obstacle. The major challenges in cancer gene therapy and antisense therapy are the lack of delivery systems that successfully deliver an effective dose of a therapeutic gene or antisense drug to the targeted tumor site. Antisense drug delivery to distant tumors for therapeutic approaches is a demanding task that urges the development of delivery vectors capable of overcoming many barriers. Many scientists have been using viral and non-viral vectors to deliver the therapeutic gene or antisense compound into the targeted tumor cells or tissues. Although the results of early gene therapy and antisense therapy-based clinical trials using either viral or non-viral vectors have been encouraging, it is still difficult to find a single method that meets all the conditions for an ideal gene transfer and vector expression.

Limitations of the present vector technologies have slowed the progress of gene therapy and antisense therapy for cancer to the clinic. Thus, the development of appropriate delivery systems for targeting therapeutic genes and antisense agents into targeted tumor cells and tissues is one of the potential approaches that have to be further explored in the future to expand gene therapy and antisense therapy against a wide range of cancers.

By product segment, the oligonucleotide-based drugs segment accounted for the largest share of the oligonucleotide synthesis market in 2020.

Based on product, the oligonucleotide synthesis market is segmented into oligonucleotide-based drugs, synthesized oligonucleotides, reagents, and equipment. In 2020, the oligonucleotide-based drugs segment held the largest share of the oligonucleotide synthesis market. The increasing number of FDA-approved drugs and a rich clinical pipeline of oligonucleotide-based drugs are factors expected to drive the growth of these therapeutics in the coming years.

By end user, hospitals accounted for the largest share of the oligonucleotide synthesis market in 2020.

 Based on end users, the oligonucleotide synthesis market is categorized into hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, contract manufacturing organizations (CMOs) and contract research organizations (CROs), and academic research institutes. In 2020, hospitals accounted for the largest share of the oligonucleotide synthesis market. Growth in this market is largely driven by the significant number of inpatient & outpatient visits in hospitals and the high requirement of oligonucleotide drugs to cater to the growing demand of patients suffering from rare diseases, neurological disorders, and infectious diseases.

By application, the therapeutic application segment accounted for the largest share of the oligonucleotide synthesis market in 2020.

Based on application, the oligonucleotide synthesis market is segmented into therapeutic applications, research applications, and diagnostic applications. In 2020, the therapeutic applications segment accounted for the largest share of the oligonucleotide synthesis market. The increasing applications of oligos as therapeutic agents (such as antisense oligos and siRNA) used in treating neurological, infectious, and rare genetic disorders are expected to drive market growth.

North America accounted for the largest share of the oligonucleotide synthesis market in 2020.

In 2020, North America accounted for the largest market share. The large share of this region can be attributed to the increasing R&D in life sciences, rising focus on improving the safety & quality of healthcare, rising demand for high-quality research tools for data reproducibility, and increasing focus on developing personalized therapeutics. The presence of many global players in this region is another key factor contributing to the large share of this market segment.

Oligonucleotide Synthesis Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The oligonucleotide synthesis market is dominated by a few globally established players such as Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), LGC Limited (UK), Maravai Life Sciences (US). The prominent players in the oligonucleotide therapeutics market are Biogen Inc. (US) and Sarepta Therapeutics, Inc. (US).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market Size Available for Years

2019–2026

Base Year Considered

2020

Forecast Period

2021–2026

Forecast Units

Value (USD)

Segments Covered

Product, Application, End User, and Region

Geographies Covered

North America, Europe, APAC , LATAM and MEA

Companies Covered

The major market players include Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), LGC Limited (UK), Maravai Life Sciences (US), and Agilent Technologies, Inc. (US). The prominent players in the oligonucleotide therapeutics market are Biogen Inc. (US) and Sarepta Therapeutics, Inc. (US).

 

The study categorizes the oligonucleotide synthesis market into the following segments and subsegments:

Oligonucleotide synthesis Market, by Product

  • Oligonucleotide-based Drugs
  • Synthesized Oligonucleotides
  • By Product
    • Primers
    • Probes
    • DNA Oligos
    • RNA Oligos
    • Other Synthesized Oligos
  • By Type
    • Customized Oligos
    • Predesigned Oligos
  • Reagents
  • Equipment

Oligonucleotide synthesis Market, by Application 

  • Research Applications
    • PCR
    • Sequencing
    • Other Research Applications
  • Diagnostic Applications

Therapeutic Applications,  By Type

  • Antisense Oligonucleotide-based Therapies 
  • RNAi Oligonucleotide-based Therapies
  • CpG Oligonucleotide-based Therapies

Therapeutic Applications, By Disease Type

  •  Neurological Disorders
  • Infectious Diseases
  • Other Diseases

Oligonucleotide synthesis Market, by End User

  •  Hospitals
  • Pharmaceutical & Biotechnology Companies
  • Diagnostic Laboratories
  • CROs and CMOs
  • Academic Research  Institutes

 Oligonucleotide synthesis Market, by Region

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • RoLATAM
  • The Middle East and Africa

Recent Developments

  • In 2020, Danaher Corporation (US) opened IDT China, an official business entity, to better serve its customer base in the region, reach out to new customers, and provide easier access to its complete portfolio of industry-leading products.
  • In 2020, Danaher (US) acquired the Biopharma business from General Electric Company's (US) Life Sciences division. This subsidiary is called ‘Cytiva’ and will act as a standalone operating company within Danaher's Life Sciences segment. This acquisition strengthened Danaher’s position in the oligo synthesizer and reagents market.
  • In 2020, Microsynth AG (Switzerland) launched Primer-Probe Sets for SARS-CoV-2.
  • In 2020, LGC Limited (UK) partnered with the Paranแ Institute of Molecular Biology (IBMP) (Brazil) to supply reliable, high-quality custom GMP oligonucleotides and molecular products to develop a new molecular test for ZDC (zika, dengue, and chikungunya).
  • In 2019, Thermo Fisher Scientific (US) entered into an agreement with BioNTech SE (Germany). Under the agreement, Thermo Fisher supplies nucleotides, enzymes, and other critical raw materials to support BioNTech's messenger RNA (mRNA) manufacturing platform. The four-year, nonexclusive licensing and supply agreement gives BioNTech rights to use Thermo Fisher's technologies as part of its clinical and commercial manufacturing processes.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 35)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 40)
    2.1 RESEARCH DATA
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                 FIGURE 1 BREAKDOWN OF PRIMARIES: OLIGONUCLEOTIDE SYNTHESIS MARKET
    2.2 MARKET DATA ESTIMATION AND TRIANGULATION
        FIGURE 2 DATA TRIANGULATION METHODOLOGY
    2.3 MARKET ESTIMATION METHODOLOGY
        FIGURE 3 MARKET SIZE ESTIMATION- COMPANY REVENUE ANALYSIS-BASED ESTIMATION (RESEARCH AND DIAGNOSTIC MARKET)
        FIGURE 4 MARKET SIZE ESTIMATION- COMPANY REVENUE ANALYSIS-BASED ESTIMATION (THERAPEUTIC MARKET)
        FIGURE 5 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE (USD MILLION)
        FIGURE 6 OLIGONUCLEOTIDE SYNTHES MARKET: FINAL CAGR PROJECTIONS (2021−2026)
        FIGURE 7 OLIGONUCLEOTIDE SYNTHES: CAGR PROJECTIONS FROM THE ANALYSIS OF DEMAND-SIDE DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
        FIGURE 8 OLIGONUCLEOTIDE SYNTHESIS: SEGMENTAL ASSESSMENT
    2.4 INDUSTRY INSIGHTS
    2.5 RESEARCH ASSUMPTIONS

3 EXECUTIVE SUMMARY (Page No. - 48)
  FIGURE 9 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2021 VS. 2026 (USD BILLION)
  FIGURE 10 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY APPLICATION, 2020
  FIGURE 11 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2021−2026
  FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE OLIGONUCLEOTIDE SYNTHESIS MARKET

4 PREMIUM INSIGHTS (Page No. - 51)
    4.1 OLIGONUCLEOTIDE SYNTHESIS MARKET OVERVIEW
        FIGURE 13 INCREASING USE OF SYNTHESIZED OLIGOS IN THERAPEUTIC APPLICATIONS IS A KEY FACTOR EXPECTED TO DRIVE MARKET GROWTH
    4.2 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION & COUNTRY (2020)
        FIGURE 14 THERAPEUTIC APPLICATIONS ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2020
    4.3 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE
        FIGURE 15 ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES SEGMENT IS PROJECTED TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 54)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
        FIGURE 16 OLIGONUCLEOTIDE SYNTHESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 The increasing use of synthesized oligos in therapeutic applications
                            TABLE 1 FDA-APPROVED OLIGONUCLEOTIDE-BASED THERAPIES (2016-2021)
                            FIGURE 17 ONGOING CLINICAL TRIALS BY TOP 10 THERAPEUTIC AREAS
                    5.2.1.2 Increasing government investments for synthetic biology and genome projects
                    5.2.1.3 Growing focus on personalized medicine
           5.2.2 RESTRAINTS
                    5.2.2.1 Complexities associated with therapeutic oligos
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Key players in emerging economies
           5.2.4 CHALLENGES
                    5.2.4.1 Delivery of oligonucleotide drugs to specific targets
    5.3 THE IMPACT OF COVID-19 ON THE OLIGONUCLEOTIDE SYNTHESIS MARKET
        TABLE 2 LIST OF PROBES AND PRIMERS USED FOR COVID-19 RESEARCH
    5.4 SUPPLY CHAIN ANALYSIS
        FIGURE 18 DIRECT DISTRIBUTION STRATEGY PREFERRED BY PROMINENT COMPANIES
           5.4.1 KEY INFLUENCERS
    5.5 PORTER’S FIVE FORCES ANALYSIS
        TABLE 3 OLIGONUCLEOTIDE SYNTHESIS MARKET- PORTER’S FIVE FORCES ANALYSIS
           5.5.1 DEGREE OF COMPETITION
           5.5.2 BARGAINING POWER OF SUPPLIERS
           5.5.3 BARGAINING POWER OF BUYERS
           5.5.4 THREAT OF SUBSTITUTES
           5.5.5 THREAT OF NEW ENTRANTS
    5.6 VALUE CHAIN ANALYSIS
        FIGURE 19 VALUE CHAIN ANALYSIS—MAXIMUM VALUE IS ADDED DURING THE MANUFACTURING PHASE
    5.7 ECOSYSTEM ANALYSIS OF THE OLIGONUCLEOTIDE SYNTHESIS MARKET
        FIGURE 20 ECOSYSTEM ANALYSIS OF THE OLIGONUCLEOTIDE SYNTHESIS MARKET
           5.7.1 ROLE IN THE ECOSYSTEM
    5.8 TECHNOLOGICAL ANALYSIS
           5.8.1 SOLID-PHASE SYNTHESIS
           5.8.2 LIQUID-PHASE SYNTHESIS
    5.9 REGULATORY ANALYSIS
           5.9.1 GOVERNMENT REGULATIONS FOR OLIGONUCLEOTIDE-BASED DRUGS:
           5.9.2 GOVERNMENT REGULATIONS FOR SYNTHESIZED OLIGONUCLEOTIDES: GOOD MANUFACTURING PRACTICE (GMP)
           5.9.3 ISO 13485
           5.9.4 IVD & ASR:
    5.10 PATENT ANALYSIS
    5.11 TRADE DATA
         TABLE 4 IMPORT DATA FOR OLIGONUCLEOTIDES, BY COUNTRY, 2016–2020 (USD THOUSAND)
    5.12 PRICING ANALYSIS

6 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT (Page No. - 73)
    6.1 INTRODUCTION
        TABLE 5 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
    6.2 OLIGONUCLEOTIDE-BASED DRUGS
           6.2.1 OLIGONUCLEOTIDE-BASED DRUGS DOMINATED THE OLIGONUCLEOTIDE SYNTHESIS MARKET IN 2020
                 TABLE 6 LATE-STAGE OLIGONUCLEOTIDE-BASED THERAPIES
                 TABLE 7 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2019–2026 (USD MILLION)
    6.3 SYNTHESIZED OLIGONUCLEOTIDES
        TABLE 8 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2019–2026 (USD MILLION)
           6.3.1 SYNTHESIZED OLIGOS MARKET, BY PRODUCT
                 TABLE 9 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                    6.3.1.1 Primers
                               6.3.1.1.1 Increasing applications for oligo primers in DNA sequencing and molecular diagnostics drive segment growth
                                         TABLE 10 PRIMERS MARKET, BY REGION, 2019–2026 (USD MILLION)
                                         TABLE 11 NORTH AMERICA: PRIMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                         TABLE 12 EUROPE: PRIMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                         TABLE 13 ASIA PACIFIC: PRIMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                         TABLE 14 LATIN AMERICA: PRIMERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.3.1.2 Probes
                               6.3.1.2.1 Probes are designed to detect various infectious agents
                                         TABLE 15 PROBES MARKET, BY REGION, 2019–2026 (USD MILLION)
                                         TABLE 16 NORTH AMERICA: PROBES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                         TABLE 17 EUROPE: PROBES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                         TABLE 18 ASIA PACIFIC: PROBES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                         TABLE 19 LATIN AMERICA: PROBES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.3.1.3 DNA oligos
                               6.3.1.3.1 Innovations in DNA oligos that eliminate time-consuming PCR drives segment growth
                                         TABLE 20 DNA OLIGOS MARKET, BY REGION, 2019–2026 (USD MILLION)
                                         TABLE 21 NORTH AMERICA: DNA OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                         TABLE 22 EUROPE: DNA OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                         TABLE 23 ASIA PACIFIC: DNA OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                         TABLE 24 LATIN AMERICA: DNA OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.3.1.4 RNA oligos
                               6.3.1.4.1 RNA oligos are widely used as molecular diagnostic tools
                                         TABLE 25 RNA OLIGOS MARKET, BY REGION, 2019–2026 (USD MILLION)
                                         TABLE 26 NORTH AMERICA: RNA OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                         TABLE 27 EUROPE: RNA OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                         TABLE 28 ASIA PACIFIC: RNA OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                         TABLE 29 LATIN AMERICA: RNA OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.3.1.5 Other synthesized oligos
                            TABLE 30 OTHER SYNTHESIZED OLIGOS MARKET, BY REGION, 2019–2026 (USD MILLION)
                            TABLE 31 NORTH AMERICA: OTHER SYNTHESIZED OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                            TABLE 32 EUROPE: OTHER SYNTHESIZED OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                            TABLE 33 ASIA PACIFIC: OTHER SYNTHESIZED OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                            TABLE 34 LATIN AMERICA: OTHER SYNTHESIZED OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.3.2 SYNTHESIZED OLIGOS MARKET, BY TYPE
                 TABLE 35 SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    6.3.2.1 Custom oligonucleotides
                               6.3.2.1.1 The increasing requirement of custom oligonucleotides for clinical and preclinical research studies in the field of molecular biology and therapeutics is expected to drive the market 
                                         TABLE 36 CUSTOMIZED OLIGOS MARKET, BY REGION, 2019–2026 (USD MILLION)
                                         TABLE 37 NORTH AMERICA: CUSTOMIZED OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                         TABLE 38 EUROPE: CUSTOMIZED OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                         TABLE 39 ASIA PACIFIC: CUSTOMIZED OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                         TABLE 40 LATIN AMERICA: CUSTOMIZED OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    6.3.2.2 Predesigned oligos
                               6.3.2.2.1 Predesigned oligos are widely used in routine research applications such as PCR and sequencing
                                         TABLE 41 PREDESIGNED OLIGOS MARKET, BY REGION, 2019–2026(USD MILLION)
                                         TABLE 42 NORTH AMERICA: PREDESIGNED OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                         TABLE 43 EUROPE: PREDESIGNED OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                         TABLE 44 ASIA PACIFIC: PREDESIGNED OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                         TABLE 45 LATIN AMERICA: PREDESIGNED OLIGOS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.4 REAGENTS
           6.4.1 THE GROWING APPLICATIONS OF OLIGOS IN SEQUENCING, DRUG DESIGN, AND GENE SYNTHESIS IS EXPECTED TO DRIVE THE MARKET GROWTH FOR REAGENTS
                 TABLE 46 REAGENTS MARKET, BY REGION, 2019–2026 (USD MILLION)
                 TABLE 47 NORTH AMERICA: REAGENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                 TABLE 48 EUROPE: REAGENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                 TABLE 49 ASIA PACIFIC: REAGENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                 TABLE 50 LATIN AMERICA: REAGENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.5 EQUIPMENT
           6.5.1 GROWTH IN THE EQUIPMENT MARKET IS MAINLY DRIVEN BY TECHNOLOGICAL INNOVATIONS IN OLIGONUCLEOTIDE SYNTHESIZERS
                 TABLE 51 EQUIPMENT MARKET, BY REGION, 2019–2026 (USD MILLION)
                 TABLE 52 NORTH AMERICA: EQUIPMENT MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                 TABLE 53 EUROPE: EQUIPMENT MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                 TABLE 54 ASIA PACIFIC: EQUIPMENT MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                 TABLE 55 LATIN AMERICA: EQUIPMENT MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

7 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION (Page No. - 96)
    7.1 INTRODUCTION
        TABLE 56 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
    7.2 THERAPEUTIC APPLICATIONS
        TABLE 57 THERAPEUTIC APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
           7.2.1 THERAPEUTIC APPLICATIONS MARKET, BY TYPE
           7.2.2 ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES
                    7.2.2.1 Antisense oligos form the basis of many therapies that are currently in clinical trials, thus boosting segment growth
           7.2.3 SIRNA OLIGONUCLEOTIDE-BASED THERAPIES
                    7.2.3.1 The ease of drug target identification with the help of bioinformatics is expected to drive segment growth
           7.2.4 CPG OLIGONUCLEOTIDE-BASED THERAPIES
                    7.2.4.1 CpG ODNs have shown significant potential for the treatment of a wide variety of diseases, including cancer
                            TABLE 58 THERAPEUTIC APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
    7.3 THERAPEUTIC APPLICATIONS MARKET, BY DISEASE TYPE
           7.3.1 NEUROLOGICAL DISORDERS
                    7.3.1.1 Neurological disorders dominated the therapeutic applications market by disease type in 2020
           7.3.2 INFECTIOUS DISEASES
                    7.3.2.1 Antisense therapies and oligonucleotide aptamers have significant potential in the treatment & diagnosis of infectious diseases
           7.3.3 OTHER DISEASES
                 TABLE 59 THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2019–2026 (USD MILLION)
    7.4 DIAGNOSTIC APPLICATIONS
        TABLE 60 DIAGNOSTIC APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
        TABLE 61 NORTH AMERICA: DIAGNOSTIC APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
        TABLE 62 EUROPE: DIAGNOSTIC APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
        TABLE 63 ASIA PACIFIC: DIAGNOSTIC APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
        TABLE 64 LATIN AMERICA: DIAGNOSTIC APPLICATIONS, BY REGION, 019–2026 (USD MILLION)
    7.5 RESEARCH APPLICATIONS
        TABLE 65 RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
        TABLE 66 NORTH AMERICA: RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
        TABLE 67 EUROPE: RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
        TABLE 68 ASIA PACIFIC: RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
        TABLE 69 LATIN AMERICA: RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
        TABLE 70 RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
           7.5.1 PCR
                    7.5.1.1 Increasing use of PCR in research to drive the market growth
                            TABLE 71 RESEARCH APPLICATIONS FOR PCR, BY REGION, 2019–2026 (USD MILLION)
                            TABLE 72 NORTH AMERICA: RESEARCH APPLICATIONS FOR PCR, BY REGION, 2019–2026 (USD MILLION)
                            TABLE 73 EUROPE: RESEARCH APPLICATIONS FOR PCR, BY REGION, 2019–2026 (USD MILLION)
                            TABLE 74 ASIA PACIFIC: RESEARCH APPLICATIONS FOR PCR, BY REGION, 2019–2026 (USD MILLION)
                            TABLE 75 LATIN AMERICA: RESEARCH APPLICATIONS FOR PCR, BY REGION, 2019–2026 (USD MILLION)
           7.5.2 SEQUENCING
                    7.5.2.1 Advancements in sequencing technologies and the low cost of DNA sequencing to boost segment growth
                            TABLE 76 RESEARCH APPLICATIONS FOR SEQUENCING, BY REGION, 2019–2026 (USD MILLION)
                            TABLE 77 NORTH AMERICA: RESEARCH APPLICATIONS FOR SEQUENCING, BY REGION, 2019–2026 (USD MILLION)
                            TABLE 78 EUROPE: RESEARCH APPLICATIONS FOR SEQUENCING, BY REGION, 2019–2026 (USD MILLION)
                            TABLE 79 ASIA PACIFIC: RESEARCH APPLICATIONS FOR SEQUENCING, BY REGION, 2019–2026 (USD MILLION)
                            TABLE 80 LATIN AMERICA: RESEARCH APPLICATIONS FOR SEQUENCING, BY REGION, 2019–2026 (USD MILLION)
           7.5.3 OTHER RESEARCH APPLICATIONS
                 TABLE 81 OTHER RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
                 TABLE 82 NORTH AMERICA: OTHER RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
                 TABLE 83 EUROPE: OTHER RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
                 TABLE 84 ASIA PACIFIC: OTHER RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
                 TABLE 85 LATIN AMERICA: OTHER RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)

8 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER (Page No. - 113)
    8.1 INTRODUCTION
        TABLE 86 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019–2026 (USD MILLION)
    8.2 HOSPITALS
           8.2.1 INCREASING FDA-APPROVALS FOR OLIGONUCLEOTIDE-BASED DRUGS DRIVES MARKET GROWTH FOR THE HOSPITALS SEGMENT
                 TABLE 87 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY REGION, 2019–2026 (USD MILLION)
    8.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
           8.3.1 GROWING APPLICATIONS OF OLIGOS IN DRUG DISCOVERY & THERAPEUTICS TO DRIVE THE GROWTH OF THIS SEGMENT
                 TABLE 88 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2026 (USD MILLION)
                 TABLE 89 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
                 TABLE 90 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
                 TABLE 91 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
                 TABLE 92 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
    8.4 DIAGNOSTIC LABORATORIES
           8.4.1 INCREASING SIGNIFICANCE OF OLIGOS IN MOLECULAR DIAGNOSTICS IS EXPECTED TO DRIVE GROWTH OF THIS SEGMENT
                 TABLE 93 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2019–2026 (USD MILLION)
                 TABLE 94 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION)
                 TABLE 95 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION)
                 TABLE 96 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION)
                 TABLE 97 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION)
    8.5 CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS (CROS AND CMOS)
           8.5.1 CMOS AND CROS PROVIDE A WIDE RANGE OF CUSTOMIZED OLIGO SERVICES; KEY FACTOR DRIVING MARKET GROWTH
                 TABLE 98 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS AND CMOS, BY REGION, 2019–2026 (USD MILLION)
                 TABLE 99 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS AND CMOS, BY COUNTRY, 2019–2026 (USD MILLION)
                 TABLE 100 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS AND CMOS, BY COUNTRY, 2019–2026 (USD MILLION)
                 TABLE 101 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS AND CMOS, BY COUNTRY, 2019–2026 (USD MILLION)
                 TABLE 102 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS AND CMOS, BY COUNTRY, 2019–2026 (USD MILLION)
    8.6 ACADEMIC RESEARCH INSTITUTES
           8.6.1 ACADEMIC AND GOVERNMENT RESEARCHERS PRIMARILY USE OLIGOS FOR GENOMIC TECHNOLOGIES
                 TABLE 103 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2019–2026 (USD MILLION)
                 TABLE 104 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
                 TABLE 105 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
                 TABLE 106 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
                 TABLE 107 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)

9 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION (Page No. - 126)
    9.1 INTRODUCTION
        TABLE 108 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2019–2026 (USD MILLION)
    9.2 NORTH AMERICA
        FIGURE 21 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
        TABLE 109 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
        TABLE 110 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
        TABLE 111 NORTH AMERICA: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
        TABLE 112 NORTH AMERICA: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019–2026 (USD MILLION)
        TABLE 113 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
        TABLE 114 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
        TABLE 115 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.2.1 US
                    9.2.1.1 Government initiatives and strategic developments by market players to drive market growth in the country
                            TABLE 116 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                            TABLE 117 US: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                            TABLE 118 US: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019-2026 (USD MILLION)
                            TABLE 119 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
                            TABLE 120 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                            TABLE 121 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019-2026 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 Strong research infrastructure and the availability of funding to support market growth
                            TABLE 122 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
                            TABLE 123 CANADA: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
                            TABLE 124 CANADA: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019-2026 (USD MILLION)
                            TABLE 125 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
                            TABLE 126 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
                            TABLE 127 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019-2025 (USD MILLION)
    9.3 EUROPE
        TABLE 128 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
        TABLE 129 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
        TABLE 130 EUROPE: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
        TABLE 131 EUROPE: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019-2026 (USD MILLION)
        TABLE 132 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
        TABLE 133 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
        TABLE 134 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019-2026 (USD MILLION)
           9.3.1 GERMANY
                    9.3.1.1 The presence of a large number of academic research institutes to support market growth in Germany
                            TABLE 135 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                            TABLE 136 GERMANY: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                            TABLE 137 GERMANY: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019-2026 (USD MILLION)
                            TABLE 138 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
                            TABLE 139 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
                            TABLE 140 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.3.2 FRANCE
                    9.3.2.1 Government initiatives to strengthen R&D activities to propel market growth
                            TABLE 141 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
                            TABLE 142 FRANCE: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
                            TABLE 143 FRANCE: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019-2026 (USD MILLION)
                            TABLE 144 RANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
                            TABLE 145 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
                            TABLE 146 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019-2026S (USD MILLION)
           9.3.3 UK
                    9.3.3.1 Increasing strategic developments by market players in the field of oligonucleotide synthesis are supporting the growth of the market in the UK
                            TABLE 147 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
                            TABLE 148 UK: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
                            TABLE 149 UK: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019-2026 (USD MILLION)
                            TABLE 150 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
                            TABLE 151 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
                            TABLE 152 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019-2026 (USD MILLION)
           9.3.4 ITALY
                    9.3.4.1 Increasing research activities to drive the market for oligonucleotides synthesis in Italy
                            TABLE 153 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
                            TABLE 154 ITALY: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
                            TABLE 155 ITALY: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019-2026 (USD MILLION)
                            TABLE 156 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
                            TABLE 157 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
                            TABLE 158 TALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019-2026 (USD MILLION)
           9.3.5 SPAIN
                    9.3.5.1 Government initiatives to drive the market for oligonucleotide synthesis
                            TABLE 159 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
                            TABLE 160 SPAIN: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
                            TABLE 161 SPAIN: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019-2026 (USD MILLION)
                            TABLE 162 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
                            TABLE 163 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019-2026 (USD MILLION)
                            TABLE 164 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019-2026 (USD MILLION)
           9.3.6 ROE
                 TABLE 165 ROE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
                 TABLE 166 ROE: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
                 TABLE 167 ROE: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019-2026 (USD MILLION)
                 TABLE 168 ROE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
                 TABLE 169 ROE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019-2026 USD MILLION)
                 TABLE 170 ROE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019-2026 (USD MILLION)
    9.4 ASIA PACIFIC
        FIGURE 22 APAC: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
        TABLE 171 APAC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
        TABLE 172 APAC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
        TABLE 173 APAC: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
        TABLE 174 APAC: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019–2026 (USD MILLION)
        TABLE 175 APAC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
        TABLE 176 APAC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
        TABLE 177 APAC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.4.1 CHINA
                    9.4.1.1 The increasing focus of Chinese biopharma companies in this country is a major factor driving market growth
                            TABLE 178 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                            TABLE 179 CHINA: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                            TABLE 180 CHINA: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                            TABLE 181 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                            TABLE 182 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                            TABLE 183 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.4.2 JAPAN
                    9.4.2.1 Various growth strategies adopted by key players in this region along with increasing awareness of oligos through conferences & workshops to drive the market growth in Japan
                            TABLE 184 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                            TABLE 185 JAPAN: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                            TABLE 186 JAPAN: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                            TABLE 187 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                            TABLE 188 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                            TABLE 189 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.4.3 INDIA
                    9.4.3.1 Strong initiatives to develop bio clusters and increasing adoption of genomic technologies is expected to aid market growth in India
                            TABLE 190 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                            TABLE 191 INDIA: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                            TABLE 192 INDIA: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                            TABLE 193 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                            TABLE 194 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                            TABLE 195 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.4.4 ROAPAC
                 TABLE 196 ROAPAC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                 TABLE 197 ROAPAC: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                 TABLE 198 ROAPAC: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                 TABLE 199 ROAPAC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                 TABLE 200 ROAPAC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                 TABLE 201 ROAPAC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019–2026 (USD MILLION)
    9.5 LATIN AMERICA
        TABLE 202 LATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
        TABLE 203 LATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
        TABLE 204 LATAM: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
        TABLE 205 LATAM: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019–2026 (USD MILLION)
        TABLE 206 LATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
        TABLE 207 LATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
        TABLE 208 LATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.5.1 BRAZIL
                    9.5.1.1 Growing prevalence of infectious and non-infectious diseases to support market growth in Brazil
                            TABLE 209 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                            TABLE 210 BRAZIL: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                            TABLE 211 BRAZIL: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                            TABLE 212 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                            TABLE 213 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                            TABLE 214 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.5.2 MEXICO
                    9.5.2.1 Increasing research in synthetic biology to drive the market growth in Mexico
                            TABLE 215 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                            TABLE 216 MEXICO: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                            TABLE 217 MAXICO: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                            TABLE 218 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                            TABLE 219 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                            TABLE 220 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.5.3 ROLATAM
                 TABLE 221 ROLATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                 TABLE 222 ROLATAM: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                 TABLE 223 ROLATAM: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                 TABLE 224 ROLATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                 TABLE 225 ROLATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                 TABLE 226 ROLATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019–2026 (USD MILLION)
    9.6 MIDDLE EAST & AFRICA
           9.6.1 THE GROWING ACCEPTANCE OF PERSONALIZED MEDICINE IS EXPECTED TO DRIVE MARKET GROWTH FOR OLIGOS
                 TABLE 227 MEA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                 TABLE 228 MEA: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                 TABLE 229 MEA: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                 TABLE 230 MEA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                 TABLE 231 MEA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                 TABLE 232 MEA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2019–2026 (USD MILLION)

10 COMPETITIVE LANDSCAPE (Page No. - 183)
     10.1 INTRODUCTION
     10.2 MARKET SHARE ANALYSIS
          FIGURE 23 OLIGONUCCLEOTIDE SYNTHESIS MARKET SHARE ANALYSIS (RESEARCH AND DIAGNOSTIC MARKET), BY KEY PLAYER, 2020
          FIGURE 24 OLIGONUCCLEOTIDE SYNTHESIS MARKET SHARE ANALYSIS (FOR THERAPEUTICS MARKET), BY KEY PLAYER, 2020
     10.3 MARKET RANKING ANALYSIS
          FIGURE 25 COMPANY RANKING IN THE OLIGONUCLEOTIDE SYNTHESIS MARKET, 2020 (RESEARCH AND DIAGNOSTIC MARKET)
     10.4 MARKET EVALUATION FRAMEWORK
          TABLE 233 MARKET EVALUATION FRAMEWORK: PRODUCT LAUNCHES AND APPROVALS— MAJOR STRATEGY ADOPTED BY MARKET PLAYERS
     10.5 MARKET REVENUE ANALYSIS
          FIGURE 26 REVENUE ANALYSIS OF TOP 5 PLAYERS (2016–2020) (THERAPEUTICS MARKET)
     10.6 COMPANY PRODUCT FOOTPRINT
          TABLE 234 PRODUCT PORTFOLIO ANALYSIS: OLIGONUCLEOTIDE SYNTHESIS MARKET
     10.7 COMPANY APPLICATION FOOTPRINT
          TABLE 235 APPLICATION ANALYSIS: OLIGONUCLEOTIDE SYNTHESIS MARKET
     10.8 COMPANY GEOGRAPHIC FOOTPRINT
          TABLE 236 GEOGRAPHIC ANALYSIS: OLIGONUCLEOTIDE SYNTHESIS MARKET
     10.9 COMPETITIVE SCENARIO
             10.9.1 KEY PRODUCT LAUNCHES
             10.9.2 DEALS
             10.9.3 OTHER DEVELOPMENTS

11 COMPANY EVALUATION MATRIX (Page No. - 192)
     11.1 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX (RESEARCH AND DIAGNOSTIC MARKET) (2020)
             11.1.1 STARS
             11.1.2 EMERGING LEADERS
             11.1.3 PERVASIVE PLAYERS
             11.1.4 PARTICIPANTS
                    FIGURE 27 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH AND DIAGNOSTIC): COMPANY EVALUATION MATRIX, 2020
     11.2 COMPANY EVALUATION MATRIX (THERAPEUTICS MARKET) (2020)
             11.2.1 STARS
             11.2.2 EMERGING LEADERS
             11.2.3 PERVASIVE PLAYERS
             11.2.4 EMERGING COMPANIES
                    FIGURE 28 COMPETITIVE LEADERSHIP MAPPING: OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTICS)

12 COMPANY PROFILES (Page No. - 196)
     12.1 MAJOR PLAYERS
(Business Overview, Products/Solutions Offered, Recent Developments, Right to Win)*
             12.1.1 DANAHER CORPORATION
                    FIGURE 29 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
             12.1.2 THERMO FISHER SCIENTIFIC, INC.
                    FIGURE 30 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020)
             12.1.3 MERCK KGAA
                    FIGURE 31 MERCK KGAA: COMPANY SNAPSHOT (2020)
             12.1.4 EUROFINS SCIENTIFIC
                    FIGURE 32 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2020)
             12.1.5 LGC LIMITED
                    FIGURE 33 LGC LIMITED: COMPANY SNAPSHOT (2020)
             12.1.6 MARAVAI LIFESCIENCES
                    FIGURE 34 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2020)
             12.1.7 AGILENT TECHNOLOGIES, INC.
                    FIGURE 35 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2020)
             12.1.8 KANEKA CORPORATION
                    FIGURE 36 KANEKA CORPORATION: COMPANY SNAPSHOT (2019)
             12.1.9 BIOLEGIO B.V.
             12.1.10 BIOLYTIC LAB PERFORMANCE INC.
             12.1.11 MICROSYNTH AG
     12.2 OTHER PLAYERS
             12.2.1 ADTBIO LTD.
             12.2.2 TWIST BIOSCIENCE CORPORATION
             12.2.3 ETON BIOSCIENCE, INC.
             12.2.4 CSBIO
             12.2.5 TAG COPENHAGEN A/S
     12.3 THERAPEUTIC PLAYERS
             12.3.1 BIOGEN INC.
                    FIGURE 37 BIOGEN: COMPANY SNAPSHOT (2020)
             12.3.2 SAREPTA THERAPEUTICS, INC.
                    FIGURE 38 SAREPTA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2020)
             12.3.3 IONIS PHARMACEUTICALS, INC.
                    FIGURE 39 IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2020)
             12.3.4 ALNYLAM PHARMACEUTICALS, INC.
                    FIGURE 40 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2020)

*Business Overview, Products/Solutions Offered, Recent Developments, Right to Win might not be captured in case of unlisted companies.

13 APPENDIX (Page No. - 240)
     13.1 DISCUSSION GUIDE
     13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     13.3 AVAILABLE CUSTOMIZATIONS
     13.4 RELATED REPORTS
     13.5 AUTHOR DETAILS

This market research study involved the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global oligonucleotide synthesis market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify critical qualitative and quantitative information and to assess market prospects. The size of the oligonucleotide synthesis market was estimated through various secondary research approaches and triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

The secondary sources referred to for this research study included publications from government sources such as the World Health Organization (WHO), Food and Drug Administration (FDA), National Center for Biotechnology Information (NCBI), Industry Association of Synthetic Biology (IASB), Biotechnology Innovation Organization (BIO), Oligonucleotide Therapeutics Society (OTS), American Society of Human Genetics (ASHG), European Society of Human Genetics (ESHG), Institutes of Health (NIH), American Chemical Society (ACS), European Diagnostic Manufacturers Association (EDMA), Biotechnology and Biological Sciences Research Council (BBSRC), National Human Genome Research Institute (NHGRI), and Genome Canada.

Secondary sources also include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations, among others. Secondary data was collected and analyzed to arrive at the overall size of the global oligonucleotide synthesis market, which was validated through primary research.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global oligonucleotide synthesis market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (such as personnel from hospitals, research centers, government, and academic institutes and diagnostic laboratories and pharmaceutical & biopharmaceutical companies) and supply-side (such as C-level and D-level executives, product managers, marketing and sales managers of key manufacturers, distributors, and channel partners, among others) across five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. Approximately 80% and 20% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

Oligonucleotide Synthesis Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Data Triangulation

After arriving at the overall size of the oligonucleotide synthesis market through the methodology mentioned above, this market was split into several segments and subsegments. Market breakdown procedures were employed, wherever applicable, to arrive at the exact market value for the key segments and subsegments. The extrapolated market data was triangulated by studying various macroindicators and regional trends from both demand and supply-side participants.

Report Objectives

  • To define, describe, and forecast the oligonucleotide synthesis market on the basis of product, application, end user, and region
  • To provide detailed information regarding the factors influencing the market growth (such as drivers, opportunities, restraints, and challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall oligonucleotide synthesis market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To profile the key players in the global oligonucleotide synthesis market and comprehensively analyze their core competencies2 and market rankings
  • To forecast the size of the market segments in North America, Europe, the Asia Pacific (APAC), Latin America, and the Middle East and Africa
  • To track and analyze competitive developments such as product launches, product approvals, expansions, acquisitions, partnerships, collaborations, and agreements in the oligonucleotide synthesis market

Available Customizations:

With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

Geographical Analysis

  • Further breakdown of the European oligonucleotide synthesis market into RoE countries
  • Further breakdown of the Asia Pacific oligonucleotide synthesis market into RoAPAC countries

Company Information

  • Detailed analysis and profiling of additional market players (up to 5)
COVID-19

Get in-depth analysis of the COVID-19 impact on the Oligonucleotide Synthesis Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Oligonucleotide Synthesis Market

Request For Special Pricing
Report Code
BT 2680
Published ON
Apr, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Oligonucleotide Synthesis Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved